References
- Sakaguchi S , YamaguchiT, NomuraT et al. Regulatory T cells and immune tolerance. Cell 133 , 775–787 (2008).
- Nishikawa H , SakaguchiS. Regulatory T cells in tumor immunity. Int. J. Cancer127 , 759–767 (2010).
- Jonuleit H , SchmittE, StassenM et al. Identification and functional characterization of human CD4+CD25+ T cells with regulatory properties isolated from peripheral blood. J. Exp. Med. 193 , 1285–1294 (2001).
- de Vries IJ , CastelliC, HuygensC et al. Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents. Clin. Cancer Res. 17 , 841–848 (2011).
- Badoual C , HansS, RodriguezJ et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin. Cancer Res. 12 , 465–472 (2006).
- Petersen RP , CampaMJ, SperlazzaJ et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 107 , 2866–2872 (2006).
- Ichihara F , KonoK, TakahashiA et al. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin. Cancer Res. 9 , 4404–4408 (2003).
- Wolf D , WolfAM, RumpoldH et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin. Cancer Res. 11 , 8326–8331 (2005).
- Kono K , KawaidaH, TakahashiA et al. CD4+CD25 high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol. Immunother. 55 , 1064–1071 (2006).
- Viehl CT , MooreTT, LiyanageUK et al. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann. Surg. Oncol. 13 , 1252–1258 (2006).
- Rudge G , BarrettSP, ScottB et al. Infiltration of a mesothelioma by IFN-γ-producing cells and tumor rejection after depletion of regulatory T cells. J. Immunol. 178 , 4089–4096 (2007).
- Maker AV , AttiaP, RosenbergSA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol.175 , 7746–7754 (2005).
- Vieweg J , SuZ, DahmP et al. Reversal of tumor-mediated immunosuppression. Clin. Cancer Res. 13 , 727S–732S (2007).
- Jacobs JF , PuntCJ, LesterhuisWJ et al. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a Phase I/II study in metastatic melanoma patients. Clin. Cancer Res. 16 , 5067–5078 (2010).
- Rech AJ , MickR, MartinS et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci. Transl. Med. 4(134) , 134ra62 (2012).
- Wuest SC , EdwanJH, MartinJF et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat. Med. 17 , 604–609 (2011).
- Callahan MK , WolchokJD, AllisonJP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin. Oncol.37 , 473–484 (2010).
- Hoffmann P , EderR, BoeldTJ et al. Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood 108 , 4260–4267 (2006).